Abstract
Biosimilars have been developed for several biologic therapeutic agents, including erythropoiesis-stimulating agents (ESAs). However, biosimilars cannot be assumed to be completely identical to the reference product, nor can two different biosimilars of the same reference product be considered equivalent. Accordingly, standards for approving biosimilars are distinct from those for generic versions of conventional pharmaceuticals.
By late 2007, two biosimilar epoetins (HX575 and SB309) had been approved by the European Medicines Agency (EMA), following a series of pharmacokinetic and pharmacodynamic equivalence studies, as well as phase 3 clinical comparability evaluations. Additionally, the results of a limited number of postauthorization interventional or observational studies and quality comparisons were published subsequently on both products.
The reported differences in glycosylation profiles between these epoetin biosimilars and their reference product, as well as the lack of long-term safety and efficacy evaluation, could indicate a need to develop a more comprehensive analysis of the available data, and to evaluate the post-authorization real-life data, in order to gain a better understanding of any potential implications of molecular structural or formulation differences on longterm safety and effectiveness.
Switching between an original reference ESA and a biosimilar (and possibly also switching between biosimilar versions of the same product) should be regarded as a change in clinical management. Clinicians need to be fully involved in such decisions. Prescribing by brand name will prevent unintentional substitution by pharmacists and allow for effective pharmacovigilance, in accordance with recent EU directives. In this review, the authors have analyzed most of the published information on the two epoetin biosimilars, HX575 and SB309, to highlight the points that healthcare providers may need to consider when assessing an epoetin biosimilar.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Teuscher A. The history of insulin. In: Insulin — A Voice for Choice. Basel, Switzerland: Karger, 2007:10–13.
Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC. Safetyrelated regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300:1887–1896.
Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol. 2010;28:28–31.
Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:411–419.
Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology, from approval to practice. Eur J Haematol. 2011;86:277–288.
Schellekens H. The first biosimilar epoetin: but how biosimilar is it? Clin J Am Soc Nephrol. 2008;3:174–178.
Schellekens H. Recombinant human erythropoietins, biosimilars and immunogenicity. J Nephrol. 2008;21:497–502.
International Nonproprietary names for biological and biotechnological substances. World Health Organization website. Available at: http://www.who.int/medicines/services/inn/BioRevforweb.pdf. Accessed Nov 26 2012.
Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005;18:473–480.
Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res. 2007;30:267–272.
Greener M. Biosimilars: extending biologicals’ benefits. European Industrial Pharmacy. 2009;3:9–11.
Guideline on similar biological medical products. Committee for Medicinal Products for Human Use, European Medicines Agency website. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelines/2009/09/WC500003517.pdf. Accessed Nov 26 2012.
Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins. Committee for Medicinal Products for Human Use, European Medicines Agency website. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089474.pdf. Accessed on: Nov 26 2012.
Kiss Z, Elliott S, Jedynasty K, Tesar V, Szegedi J. Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact. Eur J Clin Pharmacol. 2010;66:331–340.
Epoetin alfa hexal European Public Assessment Report (EPAR) scientific discussion 2007. European Medicines Agency website. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000726/WC500028287.pdf. Accessed Nov 26 2012.
Brinks V, Hawe A, Basmeleh AH, et al. Quality of original and biosimilar epoetin products. Pharmaceutical Research. 2011;28:386–393.
Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple IV administrations: an open-label randomised controlled trial. BMC Clin Pharmacol. 2009;9:10.
Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. Int J Clin Pharmacol Ther. 2009;47:391–401.
Haag-Weber M, Vetter A, Thyroff-Friesinger U; INJ-9 Study Group. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol. 2009;72:380–390.
Hörl WH, Locatelli F, Haag-Weber M, Ode M, Roth K; Epo-PASS study group. Prospective multicenter study of HX575 (biosimilar epoetin-I+/−) in patients with chronic kidney disease applying a target hemoglobin of 10–12 g/dl. Clin Nephrol. 2012;78:24–32.
Jelkmann W. Biosimilar epoetins and other followon biologics: update on the European experiences. Am J Hematol. 2010;85:771–780.
Seidl A, Hainzl O, Richter M, et al. Tungsteninduced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29:1454–1467.
Lissy M, Ode M, Roth K. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study. Drugs R D. 2011;11:61–75.
European Medicines Agency, Retacrit European Public Assessment Report (EPAR). Scientific discussion. 2007. European Medicines Agency website. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000872/WC500054374.pdf. Accessed Nov 26 2012.
Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011;100:354–387.
Kirkov V, Dimitrova V, Siebert-Weigel M, et al. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 1st communication: a monocentric, open, randomized, single dose, two-period crossover trial in healthy volunteers. Arzneimittelforschung. 2008;58:215–219.
Kirkov V, Dimitrova V, Siebert-Weigel M, et al. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 2nd communication: a monocentric, double-blind, randomized, single dose, three-period crossover trial in healthy volunteers. Arzneimittelforschung. 2008;58:220–224.
Krivoshiev S, Todorov V, Manitius J, Scigalla P, Koytchev R; Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia. Curr Med Res Opin. 2008;24:1407–1415.
Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008;24:625–637.
Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Wiegel M, Koytchev R, Bronn A. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008;25:1215–1228.
Wieçek A, Ahmed I, Scigalla P, Koytchev R. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: posthoc analysis. Adv Ther. 2010;27:941–952.
Krivoshiev S, Wizemann V, Czekalski S; Epoetin Zeta Study Group. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther. 2010;27:105–117.
Schellekens H. Biosimilars: the long and winding road to clinical equivalence. Hosp Pharm Eur. 2009;47. Hospital Pharmacy Europe website. Available at: http://www.hospitalpharmacyeurope.com/default.asp?title=Biosimilars%3A%5Fthe%5Flong%5Fand%5Fwinding%5Froad%5Fto%5Fclinical%5Fequivalence&page=article.display&article.id=19174. Accessed Nov 26 2012.
Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis. 2010;10:90–97.
Kerwin B, Smalling R, Deechongkit S, Swanson S. Questions remain about drug-induced PRCA: what hospital pharmacists need to know. EJHP-P. 2005;2:42–45. Available at: http://archive.eahp.eu/Media/Home-page/EJHP-BMJ/EJHP-Practicearchive/Issue-2-2005/Industry-science/Questions-Remain-About-Drug-induced-PRCA-What-Hospital-Pharmacists-Need-to-Know. Accessed Nov 26 2012.
Macdougall IC. Pure red cell aplasia with antierythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Curr Med Res Opinion. 2004;20:83–86.
Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005;67:2346–2353.
Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011;80:88–92.
2010 pharmacovigilance legislation. Article 102e, Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010. Official Journal of the European Union 31.12.2010. European Medicines Agency website. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000492.jsp. Accessed Nov 26 2012.
Questions and answers on biological medicines (similar biological medicinal products). European Medicines Agency website. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf. Accessed Nov 26 2012.
Author information
Authors and Affiliations
Corresponding author
Additional information
To view enhanced content go to www.advancesintherapy.com
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Mikhail, A., Farouk, M. Epoetin Biosimilars in Europe: Five Years On. Adv Therapy 30, 28–40 (2013). https://doi.org/10.1007/s12325-012-0072-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-012-0072-2